Effect of inactivated whole-virion concentrated purified vaccine for the prevention of COVID-19 on clinical and biochemical blood parameters of immature rats
Introduction. The prevalence of new coronavirus infection (COVID-19) in 2021-2022 in the pediatric population was 9.5%, and fatal outcomes began to be recorded. In 2022–2023, the proportion of children infected with COVID-19 increased to 18%. Developing a vaccine for the pediatric population is an u...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Central Research Institute for Epidemiology
2025-04-01
|
| Series: | Вопросы вирусологии |
| Subjects: | |
| Online Access: | https://virusjour.crie.ru/jour/article/viewFile/16728/971 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction. The prevalence of new coronavirus infection (COVID-19) in 2021-2022 in the pediatric population was 9.5%, and fatal outcomes began to be recorded. In 2022–2023, the proportion of children infected with COVID-19 increased to 18%. Developing a vaccine for the pediatric population is an urgent task.
The aim of the study is to explore the effect of the vaccine on the parameters of general and biochemical blood tests in immature rats.
Materials and methods. The study was performed on 112 immature rats (60 females, 52 males) of the Wistar line. Animals were randomized into groups that received the CoviVac vaccine at doses of 0.125, 0.25 and 0.5 mL/animal or placebo (0.5 mL/animal), intramuscularly on days 1, 15, 29 and 43 of the experiment. General and biochemical blood tests were performed twice, on the 57th and 71st days.
Results. Oligocythemia (0.25 and 0.5 mL/animal, p 0.05), leukocytosis and thrombocytopenia (0.5 mL/animal, p 0.05) were recorded in males. Monocytopenia (0.5 mL/animal, p 0.05) and leukopenia (0.25 mL/animal, p 0.05) were established in females. In males, an increase in the amount of globulins and total protein (0.5 mL/animal), a decrease in the A/G ratio (doses 0.25 and 0.5 mL/animal), a decrease in the cholesterol level (0.125 mL/animal) were detected. In females, an increase in the amount of albumin and total protein (0.5 mL/animal, p 0.05), a decrease in the level of triglycerides (0.125, 0.25, 0.5 mL/animal, placebo, p 0.05), a decrease in the level of lactate dehydrogenase, triglycerides and urea (0.25 mL/animal, p 0.05) were recorded.
Conclusion. The safety of the CociVac vaccine in relation to clinical and biochemical blood parameters has been demonstrated. |
|---|---|
| ISSN: | 0507-4088 2411-2097 |